SCHEMBL432302

SCHEMBL432302

C/C=C/C(=C/C=C/CCCCCCCCCCC)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.51
PTPN1 P18031 4/20 0.49
KDM4E B2RXH2 1/20 0.48
TERT O14746 3/20 0.46
PPARG P37231 3/20 0.46
PPARD Q03181 3/20 0.46
PPARA Q07869 3/20 0.46
MAPT P10636 2/20 0.46
BLM P54132 2/20 0.46
HSD17B10 Q99714 2/20 0.46
FABP4 P15090 2/20 0.46
TOP1 P11387 2/20 0.46
GMNN O75496 1/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46
APEX1 P27695 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL432303 1.00 FASN (0.51) FASNPTPN1KDM4ETERTPPARG
SCHEMBL10423108 1.00 FASN (0.51) FASNPTPN1KDM4ETERTPPARG
SCHEMBL10423107 1.00 FASN (0.51) FASNPTPN1KDM4ETERTPPARG
SCHEMBL30367114 1.00 FASN (0.51) FASNPTPN1KDM4ETERTPPARG
SCHEMBL18301262 0.93 FASN (0.42) FASNPTPN1KDM4ETERTPPARG
SCHEMBL18301263 0.93 FASN (0.42) FASNPTPN1KDM4ETERTPPARG
SCHEMBL432723 0.87 PTPN1 (0.53) FASNPTPN1TERTPPARGPPARD
SCHEMBL432724 0.87 PTPN1 (0.53) FASNPTPN1TERTPPARGPPARD
SCHEMBL429510 0.86 FAAH (0.49) FASNPTPN1KDM4EMAPTBLM
SCHEMBL429511 0.86 FAAH (0.49) FASNPTPN1KDM4EMAPTBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507221-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO Aquinox Pharmaceuticals Inc. (CA) 2012-10-10 EP disclosed
US-8101605-B2 SHIP1 modulators and methods related thereto AQUINOX PHARMACEUTICALS INC. (CA) 2012-01-24 US disclosed
WO-2011069118-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2011-06-09 WO disclosed
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO AQUINOX PHARMACEUTICALS INC. (CA) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136802-A1 SHIP1 MODULATORS AND METHODS RELATED THERETO PPM1D, PTPRO, PPM1G FASN 4622/4885PTPN1 22/4885KDM4E 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.